(Q37828064)

23 August 2017

1 reference

title

Contemporary management of low-risk bladder cancer (English)

1 reference

23 August 2017

Johannes Falke

1

1 reference

23 August 2017

J Alfred Witjes

series ordinal

2

1 reference

23 August 2017

language of work or name

English

0 references

publication date

1 January 2011

1 reference

23 August 2017

published in

Nature Reviews Urology

1 reference

23 August 2017

volume

8

1 reference

23 August 2017

issue

1

1 reference

23 August 2017

page(s)

42-49

1 reference

The present and future burden of urinary bladder cancer in the world

23 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.208

21 January 2018

Cancer statistics, 2010

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.208

Clinical model of lifetime cost of treating bladder cancer and associated complications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.208

EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.208

Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.208

Recurrence and progression of disease in non-muscle-invasive bladder cancer: from epidemiology to treatment strategy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.208

Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.208

21 January 2018

Focus on bladder cancer

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.208

Molecular subtypes of bladder cancer: Jekyll and Hyde or chalk and cheese?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.208

Molecular pathogenesis of bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.208

Molecular genetics of bladder cancer: Emerging mechanisms of tumor initiation and progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.208

Molecular pathways in invasive bladder cancer: new insights into mechanisms, progression, and target identification

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.208

Urothelial tumorigenesis: a tale of divergent pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.208

Biology of urothelial tumorigenesis: insights from genetically engineered mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.208

Identification of p53 gene mutations in bladder cancers and urine samples

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.208

Urothelial dysplasia and other flat lesions of the urinary bladder: clinicopathologic and molecular features

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.208

Concurrent mutations of coding and regulatory sequences of the Ha-ras gene in urinary bladder carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.208

Localization of the normal allele of T24 human bladder carcinoma oncogene to chromosome 11.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.208

Mutations in TP53, but not FGFR3, in urothelial cell carcinoma of the bladder are influenced by smoking: contribution of exogenous versus endogenous carcinogens.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.208

Molecular grading of urothelial cell carcinoma with fibroblast growth factor receptor 3 and MIB-1 is superior to pathologic grade for the prediction of clinical outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.208

Role of FGFR3 in urothelial cell carcinoma: biomarker and potential therapeutic target

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.208

FGFR3 mutations and a normal CK20 staining pattern define low-grade noninvasive urothelial bladder tumours.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.208

Prospective study of FGFR3 mutations as a prognostic factor in nonmuscle invasive urothelial bladder carcinomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.208

PIK3CA mutations are an early genetic alteration associated with FGFR3 mutations in superficial papillary bladder tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.208

FGFR3 and Ras gene mutations are mutually exclusive genetic events in urothelial cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.208

FGFR3 protein expression and its relationship to mutation status and prognostic variables in bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.208

Superimposed histologic and genetic mapping of chromosome 9 in progression of human urinary bladder neoplasia: implications for a genetic model of multistep urothelial carcinogenesis and early detection of urinary bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.208

Bladder neoplasms--regions at chromosome 9 with putative tumour suppressor genes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.208

The association between smoking, beverage consumption, diet and bladder cancer: a systematic literature review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.208

International Commission for Protection against Environmental Mutagens and Carcinogens. ICPEMC working paper 2/3: carcinogens and carcinogenesis enhancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.208

Sequence variant on 8q24 confers susceptibility to urinary bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.208

Genetic variation in the prostate stem cell antigen gene PSCA confers susceptibility to urinary bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.208

Sequence variants at the TERT-CLPTM1L locus associate with many cancer types

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.208

A sequence variant at 4p16.3 confers susceptibility to urinary bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.208

Familial aggregation of urothelial cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.208

Frequency of fibroblast growth factor receptor 3 mutations in sporadic tumours.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.208

Loss of heterozygosity at 4p16.3 and mutation of FGFR3 in transitional cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.208

Urine markers for bladder cancer surveillance: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.208

Molecular screening for bladder cancer: progress and potential.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.208

Molecular markers for detection, surveillance and prognostication of bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.208

The pathology of bladder cancer: An update on selected issues

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.208

The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference Committee

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.208

Histologic grading of noninvasive papillary urothelial neoplasms

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.208

Prognostic accuracy of individual uropathologists in noninvasive urinary bladder carcinoma: a multicentre study comparing the 1973 and 2004 World Health Organisation classifications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.208

The pathologist's mean grade is constant and individualizes the prognostic value of bladder cancer grading.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.208

The influence of review pathology on study outcome of a randomized multicentre superficial bladder cancer trial. Members of the Dutch South East Cooperative Urological Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.208

Review pathology in a diagnostic bladder cancer trial: effect of patient risk category

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.208

Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette-Guerin: the CUETO scoring model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.208

A phase III, multicenter comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of superficial papillary lesions in patients with bladder cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.208

Fluorescence photodetection of neoplastic urothelial lesions following intravesical instillation of 5-aminolevulinic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.208

Improved detection of urothelial carcinoma in situ with hexaminolevulinate fluorescence cystoscopy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.208

Photodynamic diagnosis in non-muscle-invasive bladder cancer: a systematic review and cumulative analysis of prospective studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.208

Effect of routine repeat transurethral resection for superficial bladder cancer: a long-term observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.208

A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.208

Single postoperative instillation of gemcitabine in patients with non-muscle-invasive transitional cell carcinoma of the bladder: a randomised, double-blind, placebo-controlled phase III multicentre study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.208

A single instillation of epirubicin after transurethral resection of bladder tumors prevents only small recurrences

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.208

Should all patients with non-muscle-invasive bladder cancer receive early intravesical chemotherapy after transurethral resection? The results of a prospective randomised multicentre study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.208

Comparison of three schedules of intravesical epirubicin in patients with non-muscle-invasive bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.208

Can early single dose instillation of epirubicin improve bacillus Calmette-Guerin efficacy in patients with nonmuscle invasive high risk bladder cancer? Results from a prospective, randomized, double-blind controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.208

Treatment of nonmuscle invading bladder cancer: do physicians in the United States practice evidence based medicine? The use and economic implications of intravesical chemotherapy after transurethral resection of bladder tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.208

Contemporary cost analysis of single instillation of mitomycin after transurethral resection of bladder tumor in a universal health care system.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.208

A surveillance schedule for G1Ta bladder cancer allowing efficient use of check cystoscopy and safe discharge at 5 years based on a 25-year prospective database

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.208

The management of superficial transitional cell carcinoma of the bladder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.208

Predicting recurrence and progression of noninvasive papillary bladder cancer at initial presentation based on quantitative gene expression profiles

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.208

Theranostic and prognostic biomarkers: genomic applications in urological malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.208

Narrow-band imaging flexible cystoscopy in the detection of recurrent urothelial cancer of the bladder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.208

The health economics of bladder cancer: a comprehensive review of the published literature.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.208

The spectrum of TP53 mutations in bladder carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.208

Molecular Grade (FGFR3/MIB-1) and EORTC Risk Scores Are Predictive in Primary Non–Muscle-Invasive Bladder Cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.208

Personal use of hair dyes and the risk of bladder cancer: results of a meta-analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.208

Urinary tract infection and risk of bladder cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.208

Relationship between schistosomiasis and bladder cancer

31 March 2020

2 references

https://api.crossref.org/works/10.1038%2FNRUROL.2010.208

31 March 2020

12 December 2020

Discrepancy between clinical and pathologic stage: impact on prognosis after radical cystectomy

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.208

Variability in the recurrence rate at first follow-up cystoscopy after TUR in stage Ta T1 transitional cell carcinoma of the bladder: a combined analysis of seven EORTC studies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.208

The value of a second transurethral resection in evaluating patients with bladder tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.208

The effect of repeat transurethral resection on recurrence and progression rates in patients with T1 tumors of the bladder who received intravesical mitomycin: a prospective, randomized clinical trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.208

Factors explaining recurrence in patients undergoing chemoimmunotherapy regimens for frequently recurring superficial bladder carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.208

Stage Ta-T1 bladder cancer: the relationship between findings at first followup cystoscopy and subsequent recurrence and progression

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.208

Expectant management of small, recurrent, noninvasive papillary bladder tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.208

Watchful waiting policy in recurrent Ta G1 bladder tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.208

A comparison of white-light cystoscopy and narrow-band imaging cystoscopy to detect bladder tumour recurrences

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.208

Alterations of the p53 gene in occupational bladder cancer in workers exposed to aromatic amines.

31 March 2020

1 reference

12 December 2020

Epidemiology and etiology of premalignant and malignant urothelial changes

1 reference

12 December 2020

Role of chromosome 9 in human bladder cancer.

1 reference

12 December 2020

The 3-month clinical response to intravesical therapy as a predictive factor for progression in patients with high risk superficial bladder cancer

1 reference

12 December 2020

Fibroblast growth factor receptor 3 is overexpressed in urinary tract carcinomas and modulates the neoplastic cell growth.

1 reference

12 December 2020

Fluorescence endoscopy with 5-aminolevulinic acid reduces early recurrence rate in superficial bladder cancer

1 reference

12 December 2020

The role and impact of pathology review on stage and grade assessment of stages Ta and T1 bladder tumors: a combined analysis of 5 European Organization for Research and Treatment of Cancer Trials

1 reference

12 December 2020

Elevated and absent pRb expression is associated with bladder cancer progression and has cooperative effects with p53.

1 reference

12 December 2020

Interobserver discrepancy using the 1998 World Health Organization/International Society of Urologic Pathology classification of urothelial neoplasms: practical choices for patient care.

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRUROL.2010.208

1 reference

23 August 2017

1 reference